Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133731 · ClinicalTrials.gov registry record · Phase 2
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 947
- Enrollment target
NCT00133731 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 947 participants.
The verdict
NCT00133731, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 947 participants
- Enrollment target
Study Summary
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
Interventions
- PROCEDURE Percutaneous Coronary Intervention
- DRUG Otamixaban (XRP0673)
- DRUG Unfractionated Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133731
The ClinicalTrials.gov registry entry for NCT00133731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 947 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Percutaneous Coronary Intervention is the first listed.
NCT00133731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00133731 about?
NCT00133731 is a clinical study titled "The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention". The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
What is the current status of trial NCT00133731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 947 participants. The study started on 2004-09. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00133731?
The interventions under investigation include: Percutaneous Coronary Intervention (PROCEDURE), Otamixaban (XRP0673) (DRUG), Unfractionated Heparin (DRUG).
Who is sponsoring clinical trial NCT00133731?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.